ATE479676T1 - Als antikoagulanzien verwendbare phenylglycinamid-derivate - Google Patents

Als antikoagulanzien verwendbare phenylglycinamid-derivate

Info

Publication number
ATE479676T1
ATE479676T1 AT06717735T AT06717735T ATE479676T1 AT E479676 T1 ATE479676 T1 AT E479676T1 AT 06717735 T AT06717735 T AT 06717735T AT 06717735 T AT06717735 T AT 06717735T AT E479676 T1 ATE479676 T1 AT E479676T1
Authority
AT
Austria
Prior art keywords
anticoagulants
derivatives usable
phenylglycinamide
phenylglycinamide derivatives
usable
Prior art date
Application number
AT06717735T
Other languages
German (de)
English (en)
Inventor
Xiaojun Zhang
Eldon Scott Priestley
Alexandra A Nirschl
Yan Zou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE479676T1 publication Critical patent/ATE479676T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06717735T 2005-01-10 2006-01-09 Als antikoagulanzien verwendbare phenylglycinamid-derivate ATE479676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64275105P 2005-01-10 2005-01-10
PCT/US2006/000571 WO2006076246A2 (fr) 2005-01-10 2006-01-09 Derives de phenylglycinamide utilises comme anticoagulants

Publications (1)

Publication Number Publication Date
ATE479676T1 true ATE479676T1 (de) 2010-09-15

Family

ID=36587246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717735T ATE479676T1 (de) 2005-01-10 2006-01-09 Als antikoagulanzien verwendbare phenylglycinamid-derivate

Country Status (9)

Country Link
US (1) US7622585B2 (fr)
EP (1) EP1856096B1 (fr)
AR (1) AR054321A1 (fr)
AT (1) ATE479676T1 (fr)
DE (1) DE602006016566D1 (fr)
ES (1) ES2349428T3 (fr)
PE (1) PE20061117A1 (fr)
TW (1) TW200637843A (fr)
WO (1) WO2006076246A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828152B1 (fr) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Composes heterocycliques utilises comme inhibiteurs du facteur viia
US7456195B2 (en) * 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
PE20071132A1 (es) * 2005-12-23 2007-12-14 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
WO2007082131A1 (fr) * 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Procédé de synthèse d’hétérocycles hydroxy-substitués
CN101500993A (zh) 2006-06-08 2009-08-05 百时美施贵宝公司 作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2099783A1 (fr) * 2006-12-20 2009-09-16 Brystol-Myers Squibb Company Inhibiteurs au lactame bicyclique du facteur viia utiles en tant qu'anticoagulants
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (fr) 2008-03-14 2018-06-27 Intellikine, LLC Inhibiteurs de kinases, et procédés d utilisation associés
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
EP2149565A1 (fr) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Dérivés de chinazoline substitués par du sulfonamide en tant que modulateurs d'immunité pour le traitement de inflammations et allergies
JP5417860B2 (ja) * 2008-08-26 2014-02-19 住友化学株式会社 α−ヒドロキシエステル類の製造方法
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2015123093A1 (fr) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
WO2015123091A1 (fr) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
EP3134408B1 (fr) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
WO2016015593A1 (fr) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
EP3371162B1 (fr) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Dérivé spirocarbamate macrocyclique comme inhibiteurs du facteur xia, compositions pharmaceutiquement acceptables et leur utilisation
EP3368036B1 (fr) 2015-10-29 2022-07-20 Merck Sharp & Dohme LLC Dérivés macrocycliques de pyridine n-oxyde en tant qu'inhibiteurs du facteur xia
WO2017158147A1 (fr) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale
WO2018039094A1 (fr) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Dérivés de pyridine-1-oxyde et leur utilisation en tant qu'inhibiteurs du facteur xia
CN112225647A (zh) * 2020-10-14 2021-01-15 河南中医药大学 一种合成5-溴-2-甲氧基苯酚的方法
CN117466714A (zh) * 2023-10-30 2024-01-30 中国科学技术大学 一种2,4-二氯-5-卤代苯酚的制备方法
CN118344240A (zh) * 2024-04-16 2024-07-16 中国科学技术大学 一种2,4-二氯-5-溴苯酚的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
AU6944696A (en) 1995-09-14 1997-04-01 Shionogi & Co., Ltd. Novel phenylacetic acid derivatives and medicinal composition containing the same
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
DK0921116T3 (da) * 1997-12-04 2003-10-06 Hoffmann La Roche N-(4-carbamimido-phenyl)-glycinamidderivater
KR20010082515A (ko) * 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
US6335324B1 (en) * 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
KR100473966B1 (ko) * 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체
EP1144373B1 (fr) * 1999-01-13 2005-10-19 Genentech, Inc. Inhibiteurs de la serine protease
US20020052343A1 (en) 1999-12-15 2002-05-02 Allen Darin Arthur Salicylamides as serine protease inhibitors
AU2001228811A1 (en) * 2000-01-26 2001-08-07 Ono Pharmaceutical Co. Ltd. Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10027025A1 (de) * 2000-05-31 2001-12-06 Merck Patent Gmbh Clycinamide
JP2004505038A (ja) 2000-08-02 2004-02-19 スミスクライン・ビーチャム・コーポレイション 脂肪酸シンターゼ阻害剤
CA2426430C (fr) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Composes biaryle utilises comme inhibiteurs de serine protease
EP1332131A2 (fr) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Derives d'acide utiles comme inhibiteurs de serines proteases
ATE438615T1 (de) * 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
DE10139060A1 (de) 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
US6642386B2 (en) 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10214832A1 (de) 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
EP1594505A4 (fr) * 2003-02-11 2008-08-13 Bristol Myers Squibb Co Derives de phenylglycine utiles en tant qu'inhibiteurs de serine protease
US7144895B2 (en) * 2003-02-11 2006-12-05 Bristol-Myers Squibb Co. Benzene acetamide compounds useful as serine protease inhibitors
US20050107409A1 (en) * 2003-03-10 2005-05-19 Boehringer Ingelheim International Gmbh Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions
DE10310278A1 (de) 2003-03-10 2004-09-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aromatische Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1828152B1 (fr) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Composes heterocycliques utilises comme inhibiteurs du facteur viia
US7456195B2 (en) 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Also Published As

Publication number Publication date
US20060166997A1 (en) 2006-07-27
PE20061117A1 (es) 2006-10-13
EP1856096B1 (fr) 2010-09-01
EP1856096A2 (fr) 2007-11-21
TW200637843A (en) 2006-11-01
DE602006016566D1 (de) 2010-10-14
WO2006076246A2 (fr) 2006-07-20
WO2006076246A3 (fr) 2006-09-28
ES2349428T3 (es) 2011-01-03
AR054321A1 (es) 2007-06-20
US7622585B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DK1928882T3 (da) (s)-n-methylnaltrexon
DK2194043T3 (da) Fremgangsmåder
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
FI20055649L (fi) Paikanmääritystekniikoita
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
DK1943406T3 (da) Byggeelement
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE549324T1 (de) Tetrahydrobenzoxazine
EP1934716A4 (fr) Architecture de composant
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
EP1916896A4 (fr) Antiandrogenes non steroidiens
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502006005207D1 (de) Bauteilen
DE502005005839D1 (de) Feldgeerät
EP1867636A4 (fr) Dérivé de pyridylméthylsulfone
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten
DE602006014973D1 (de) Neuartige cercosporamidderivate
DE502006001397D1 (de) Lagerbuchse
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006001004D1 (de) Hydrolager

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties